Cancer screening saves lives. Mammography, colonoscopy, cervical screening, PSA testing, and low-dose CT have all pushed detection earlier, into the window where treatment tends to work best.

Guidelines have made that progress possible. But they are also built for populations, and cancer risk is individual.

Decisive thresholds make these guidelines usable. “Started at 45.” “Twenty pack-years.” “Quit within the last 15 years.” A clinician needs lines that can be readily applied in a short visit, and a payer needs lines to reimburse against. Biology draws none of those lines. Nobody becomes susceptible to colorectal cancer on the morning of their forty-fifth birthday, and a former smoker’s lungs do not reset on the fifteenth anniversary of the last cigarette.

A guideline can tell you whether people in the same category as your patient tend to benefit, on average, from screening. What it cannot tell you is how one particular patient’s factors add up.

The Patients Who Fall Between the Rules

David is 63, with roughly 25 pack-years behind him and no cigarettes in 18 years. He feels fine and has no symptoms.

Under the current U.S. Preventive Services Task Force recommendation, he does not qualify for annual low-dose CT screening because he quit more than 15 years ago. The American Cancer Society uses broader criteria with no years-since-quitting limit, so under ACS he does qualify. Two respected bodies, the same patient, opposite answers.

Also, David’s smoking history is not the only relevant factor in his chart. He also lived for years in a home with elevated radon. He has mild COPD with emphysema. Lung cancer runs in his family, and he carries genetic variants associated with elevated susceptibility.

No single one of those facts is highly predictive. The question worth asking is what they mean together, and what David’s actual probability of a lung cancer diagnosis looks like over the next several years.

Maya is 42. No symptoms, no prior polyps, no first-degree relative with colorectal cancer, no Lynch syndrome or familial adenomatous polyposis. Average-risk colorectal screening generally begins at 45, so the conventional guideline is to wait another three years for a colonoscopy.

However, Maya’s chart also shows other relevant information as well:

• Type 2 diabetes
• A body mass index of 32
• A history of smoking
• Low physical activity
• A second-degree relative diagnosed with colorectal cancer at 52
• A colorectal cancer polygenic risk score in the 92nd percentile (a measure of the combined effect of many common genetic variants, each of which contributes only a small amount of risk on its own)

Maya is not the patient most early-screening rules were written for. She has no single overwhelming risk factor, but six moderate risk factors all pointing in the same direction.

Patients like David and Maya fall into zones of risk that current diagnostic protocols too often render invisible. Guidelines evaluate their risk factors one at a time and assess the significance of each factor separately. What no guideline accounts for is the pattern.

What the Dynamic Risk Engine Does

PreOncology’s Dynamic Risk Engine, or DRE, estimates an individual’s probability of developing a specific cancer over the next one, five, and ten years. It draws on age, clinical history, family history, behavior, environmental exposure, prior screening results, social factors, and genetics.

Counting risk factors would be the wrong approach because not all risk is not additive. Ten weak factors do not add up to high risk, and one strong factor can outweigh several small ones. What matters is how they interact.

That is why the DRE runs several computational models instead of one. Different models see different shapes of risk. One captures the gradual accumulation that comes with age, along with the patient’s cumulative exposure to environmental risk factors. Another finds nonlinear interactions, like the way David’s smoking history hits harder against a background of emphysema. A third identifies conditional effects, such as cases where a genetic variant becomes informative only when paired with family history or a particular clinical phenotype. Together they account for more of the ways risk actually accumulates in real patients than any single model applied to everyone.

The Data and Validation Process

PreOncology works with research datasets covering more than three million participants. They include the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO); the National Lung Screening Trial (NLST); the Multiethnic Cohort; the Women’s Health Initiative; the Framingham Heart Study; the Cardiovascular Health Study; CARDIA; the Jackson Heart Study; and UK Biobank. These datasets allow comparison between people who went on to develop cancer and people who did not, with clinical, behavioral, environmental, and genetic information recorded before any diagnosis.

The mix is deliberate. PLCO and NLST were built around screening itself. The cardiovascular cohorts contribute decades of phenotype measures from people who were never enrolled with cancer in mind. The Multiethnic Cohort and the Jackson Heart Study allow us to assess whether a model still holds outside the populations that dominate most genetic research.

Each cancer model is trained on the cohorts and variables appropriate to that cancer, then tested in separate populations. Because the data are longitudinal, the models estimate whether someone will develop a specific cancer inside a clinically useful window, which is a harder and more useful question than distinguishing cancer patients from healthy individuals after the fact.

We also measure performance across sex, ancestry, age, and other relevant characteristics. Calibration matters most. If a model puts five-year risk at 2 percent, then roughly 2 in 100 comparable people should receive that diagnosis within five years. A model that ranks patients correctly but overstates everyone’s absolute risk will push people toward tests they do not need.

What the DRE Produces

For each cancer, the DRE reports the patient’s absolute risk at one, five, and ten years; where that level of risk sits relative to an appropriate reference population; which factors are driving the estimate; and how the number moves when new information arrives.

It is not a diagnosis, and it does not order a test. It gives a patient and a clinician something specific to talk about.

Better Targeting

Personalized risk assessment should not lead to earlier and more frequent screenings for everyone. Every additional test carries risks like false positives, follow-up procedures, anxiety, radiation exposure, and high costs. All of those downsides land on real people, too.

The goal of this assessment is to identify the patients who stand to gain from extra attention and to leave everyone else on the standard pathway. Guidelines will remain crucial to cancer prevention. But with respect to the goal of making the best screening decisions for individual patients, the DRE delivers predictive power far outstripping the significance of any population-level guideline.